| Dr Miki Lyn Zilnicki, OD | |
|
25 Cranberry St, Suite A, Riverhead, NY 11901-2762 | |
| (631) 740-9384 | |
| (631) 740-9385 |
| Full Name | Dr Miki Lyn Zilnicki |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 11 Years |
| Location | 25 Cranberry St, Riverhead, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063852986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | TUV007991-1 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Twin Forks Optometry Pllc | 1557678422 | 2 |
News Archive
Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
Health authorities in the U.S. are advising doctors to stop using two drugs to treat this winters influenza because it has become evident that the most common strain has become resistant to the drugs and they are unlikely to work.
Cutting aid to Rwanda because of its alleged role in the ongoing conflict in the Democratic Republic of Congo (DRC), which is outlined in a November 2012 U.N. Security Council-commissioned report, "is the wrong approach," Tony Blair, founder of the Africa Governance Initiative, and Howard Buffett, president of the Howard G. Buffett Foundation, write in a Foreign Policy opinion piece, noting that the report, containing "allegations the government strongly denies, ... has led a number of Western governments and multilaterals to suspend aid to Rwanda, totaling $245 million."
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 8 days ago
| Provider Name | Empire Vision Center Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1750358826 PECOS PAC ID: 4688573876 Enrollment ID: O20040107000405 |
News Archive
Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
Health authorities in the U.S. are advising doctors to stop using two drugs to treat this winters influenza because it has become evident that the most common strain has become resistant to the drugs and they are unlikely to work.
Cutting aid to Rwanda because of its alleged role in the ongoing conflict in the Democratic Republic of Congo (DRC), which is outlined in a November 2012 U.N. Security Council-commissioned report, "is the wrong approach," Tony Blair, founder of the Africa Governance Initiative, and Howard Buffett, president of the Howard G. Buffett Foundation, write in a Foreign Policy opinion piece, noting that the report, containing "allegations the government strongly denies, ... has led a number of Western governments and multilaterals to suspend aid to Rwanda, totaling $245 million."
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 8 days ago
| Provider Name | Twin Forks Optometry Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1699155549 PECOS PAC ID: 1557678422 Enrollment ID: O20150910001030 |
News Archive
Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
Health authorities in the U.S. are advising doctors to stop using two drugs to treat this winters influenza because it has become evident that the most common strain has become resistant to the drugs and they are unlikely to work.
Cutting aid to Rwanda because of its alleged role in the ongoing conflict in the Democratic Republic of Congo (DRC), which is outlined in a November 2012 U.N. Security Council-commissioned report, "is the wrong approach," Tony Blair, founder of the Africa Governance Initiative, and Howard Buffett, president of the Howard G. Buffett Foundation, write in a Foreign Policy opinion piece, noting that the report, containing "allegations the government strongly denies, ... has led a number of Western governments and multilaterals to suspend aid to Rwanda, totaling $245 million."
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Miki Lyn Zilnicki, OD 25 Cranberry St, Suite A, Riverhead, NY 11901-2762 Ph: (631) 740-9384 | Dr Miki Lyn Zilnicki, OD 25 Cranberry St, Suite A, Riverhead, NY 11901-2762 Ph: (631) 740-9384 |
News Archive
Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
Health authorities in the U.S. are advising doctors to stop using two drugs to treat this winters influenza because it has become evident that the most common strain has become resistant to the drugs and they are unlikely to work.
Cutting aid to Rwanda because of its alleged role in the ongoing conflict in the Democratic Republic of Congo (DRC), which is outlined in a November 2012 U.N. Security Council-commissioned report, "is the wrong approach," Tony Blair, founder of the Africa Governance Initiative, and Howard Buffett, president of the Howard G. Buffett Foundation, write in a Foreign Policy opinion piece, noting that the report, containing "allegations the government strongly denies, ... has led a number of Western governments and multilaterals to suspend aid to Rwanda, totaling $245 million."
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 8 days ago
A & H Optometry Care P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1768 Old Country Rd, Riverhead, NY 11901 Phone: 631-655-0125 | |
Taylor Elizabeth Rado, Optometrist Medicare: Medicare Enrolled Practice Location: 54 Commerce Ave, Riverhead, NY 11901 Phone: 631-727-0880 | |
Dr. Cynthia Jarah Wiener, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 887 Old Country Rd, Riverhead, NY 11901 Phone: 631-727-2858 | |
National Vision Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1094 Old Country Rd, Riverhead, NY 11901 Phone: 631-655-0290 | |
Dr. Jeffrey Slaney Williams Sr., O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 887 Old Country Rd, Suite K-l, Riverhead, NY 11901 Phone: 631-727-2858 Fax: 631-727-2866 | |
David Anthony Rodriguez, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1094 Old Country Rd, Riverhead, NY 11901 Phone: 631-655-0290 |